source
- Nobel-winning optogenetics sees growing biotech interestKarl Deisseroth, a Stanford psychiatrist and bioengineer, learned he had shared the 2026 Nobel Prize in Physiology or Medicine for pioneering optogenetics, a method that makes neurons responsive to…
- City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debutCity Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell a…